130 related articles for article (PubMed ID: 32218658)
21. Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.
Aoki T; Akiba T; Nishiyama J; Tajiri S; Hayama N; Takahashi G; Tanaka J; Sato M; Takiguchi H; Tomomatsu H; Tomomatsu K; Takihara T; Niimi K; Oguma T; Kohno M; Masuda R; Urano T; Itoh H; Kajiwara H; Nakamura N; Kunieda E; Matsumae M; Iwazaki M; Asano K
Respir Res; 2019 Nov; 20(1):263. PubMed ID: 31752884
[TBL] [Abstract][Full Text] [Related]
22. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
Hansen RN; Zhang Y; Seal B; Ryan K; Yong C; Darilay A; Ramsey SD
BMC Cancer; 2020 Apr; 20(1):276. PubMed ID: 32248816
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
[TBL] [Abstract][Full Text] [Related]
24. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
25. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
26. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
27. Treatment of non-small-cell lung cancer: the Chinese experience in a general teaching hospital.
Chen YM; Chao JY; Tsai CM; Shiau CY; Liang MJ; Yen SH; Perng RP
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):459-66. PubMed ID: 10925536
[TBL] [Abstract][Full Text] [Related]
28. Palliative care and psychosocial care in metastatic non-small cell lung cancer: factors affecting utilisation of services and impact on patient survival.
Duggan KJ; Wiltshire J; Strutt R; Boxer MM; Berthelsen A; Descallar J; Vinod SK
Support Care Cancer; 2019 Mar; 27(3):911-919. PubMed ID: 30066201
[TBL] [Abstract][Full Text] [Related]
29. Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008-2012.
Peters BJM; Cramer-Vd Welle CM; Smit AAJ; Schramel FMNH; van de Garde EMW;
Cancer Epidemiol; 2017 Dec; 51():1-6. PubMed ID: 28963913
[TBL] [Abstract][Full Text] [Related]
30. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
31. Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
Moore S; Leung B; Wu J; Ho C
Am J Clin Oncol; 2019 Mar; 42(3):292-297. PubMed ID: 30608237
[TBL] [Abstract][Full Text] [Related]
32. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
33. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
[TBL] [Abstract][Full Text] [Related]
34. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
Kwint M; Walraven I; Burgers S; Hartemink K; Klomp H; Knegjens J; Verheij M; Belderbos J
Lung Cancer; 2017 Oct; 112():134-139. PubMed ID: 29191586
[TBL] [Abstract][Full Text] [Related]
35. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
36. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
[TBL] [Abstract][Full Text] [Related]
37. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
Vyfhuis MAL; Burrows WM; Bhooshan N; Suntharalingam M; Donahue JM; Feliciano J; Badiyan S; Nichols EM; Edelman MJ; Carr SR; Friedberg J; Henry G; Stewart S; Sachdeva A; Pickering EM; Simone CB; Feigenberg SJ; Mohindra P
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):445-452. PubMed ID: 29559292
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M
Int J Clin Oncol; 2020 Jan; 25(1):67-73. PubMed ID: 31506751
[TBL] [Abstract][Full Text] [Related]
39. Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.
Faehling M; Schwenk B; Kramberg S; Fallscheer S; Leschke M; Sträter J; Eckert R
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2059-2066. PubMed ID: 30062488
[TBL] [Abstract][Full Text] [Related]
40. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
Guberina N; Pöttgen C; Schuler M; Guberina M; Stamatis G; Plönes T; Krebs B; Metzenmacher M; Theegarten D; Gauler T; Jöckel KH; Darwiche K; Aigner C; Stuschke M; Eberhardt WE
Eur J Cancer; 2020 Oct; 138():156-168. PubMed ID: 32889370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
